The Liver Center of the University of California, San Francisco (UCSF) is an interdisciplinary consortium of 82 basic and clinical scientists dedicated to understanding the biology and pathobiology of the liver and the treatment of liver diseases. Research by Center members is categorized under three basic biological themes: (1) Liver Injury and Repair, (2) Progenitor Cells, Growth and Development and (3) Hepatic Physiology and Metabolism. Across all themes, research spans bench to bedside, with approximately half of Center members being directly involved in clinical and translational studies. From 2008-2013 the Center will support three Biomedical Research Cores: (1) Cell Biology, (2) Liver Immunology &Cell Analysis and (3) Pathology. A Clinical Component, which offers biostatistical support to supplement the services offered by the UCSF Clinical and Translational Science Institute, is part of the Administrative Core. Also within the Administrative Core is the Tool &Technology Program;this is a """"""""user-defined"""""""" or """"""""a la carte"""""""" core designed to support member use of core services at UCSF not provided directly by the Center. The goals of the Center are to provide research support, technical training, a venue for new collaborations and an entry point for new members. The Center also fosters scientific exchange through an Enrichment Program that features seminars by local and visiting scientists, quarterly mini-symposia highlighting each research theme, and an annual 1-day symposium with a lively poster session. A vital component of the Center is its Pilot/Feasibility Program, which provides seed money to junior investigators and scientists new to investigative hepatology. This award program, like the cores, is an important recruitment vehicle. The Center continues to expand its support of member science through strategic partnerships with the Gladstone Institutes and affiliations, with other organized research units at UCSF. The funding base of the Center continues to grow, and support from the institution is sustained and strong. Opportunities for basic biologic discovery and the application of basic science to clinical liver disease are numerous;the Center is poised to catalyze achievements in these areas.

Public Health Relevance

The UCSF Liver Center provides a valuable research infrastructure and a scientific home to scientists who study liver biology and disease. The Center's core facilities offer high-quality, liver-focused services;the consortium creates a platform for exchange of ideas. Overall the environment of a Center accelerates scientific discovery and enhances the productivity and fulfillment of its members.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK026743-31
Application #
8451695
Study Section
Special Emphasis Panel (ZDK1-GRB-8 (O2))
Program Officer
Podskalny, Judith M,
Project Start
1996-12-01
Project End
2018-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
31
Fiscal Year
2013
Total Cost
$1,177,188
Indirect Cost
$427,188
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Li, Lei; Che, Li; Wang, Chunmei et al. (2016) [(11)C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice. Mol Imaging Biol 18:360-7
Flemming, Jennifer A; Saxena, Varun; Shen, Hui et al. (2016) Facility- and Patient-Level Factors Associated with Esophageal Variceal Screening in the USA. Dig Dis Sci 61:62-9
Pierce, Andrew A; Duwaerts, Caroline C; Soon, Russell K et al. (2016) Isocaloric manipulation of macronutrients within a high-carbohydrate/moderate-fat diet induces unique effects on hepatic lipogenesis, steatosis and liver injury. J Nutr Biochem 29:12-20
Mehta, Neil; Sarkar, Monika; Dodge, Jennifer L et al. (2016) Intention to treat outcome of T1 hepatocellular carcinoma with the ""wait and not ablate"" approach until meeting T2 criteria for liver transplant listing. Liver Transpl 22:178-87
Valcour, Victor G; Rubin, Leah H; Obasi, Mary U et al. (2016) Liver Fibrosis Linked to Cognitive Performance in HIV and Hepatitis C. J Acquir Immune Defic Syndr 72:266-73
Baeza-Raja, Bernat; Sachs, Benjamin D; Li, Pingping et al. (2016) p75 Neurotrophin Receptor Regulates Energy Balance in Obesity. Cell Rep 14:255-68
Ding, Ning; Che, Li; Li, Xiao-Lei et al. (2016) Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice. World J Gastroenterol 22:2071-80
Peters, Marion G; Bacchetti, Peter; Boylan, Ross et al. (2016) Enhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV. AIDS 30:723-9
Mehta, Neil; Heimbach, Julie; Hirose, Ryutaro et al. (2016) Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy? Gastroenterology 150:533-4
Lai, Jennifer C; Dodge, Jennifer L; Sen, Saunak et al. (2016) Functional decline in patients with cirrhosis awaiting liver transplantation: Results from the functional assessment in liver transplantation (FrAILT) study. Hepatology 63:574-80

Showing the most recent 10 out of 949 publications